Connect with us

News

Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

gbafNews28

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that it presented the latest results from three Phase III studies from the Tecentriq (atezolizumab) clinical development program in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. We are proud of our work to address challenges and advance scientific understanding of cancer immunotherapy in the context of distinct chemotherapy regimens and in various TNBC treatment settings. Although the IMpassion131 study did not reach its endpoint, we are pleased to bring new treatment options for some TNBC patients, and remain committed to improving the lives of all women with early and advanced stages of this disease.

Results from the Phase III IMpassion031 study, evaluating Tecentriq in combination with chemotherapy (Abraxane [albumin-bound paclitaxel; nab-paclitaxel]; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy (including nab-paclitaxel) demonstrated a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early TNBC, regardless of PD-L1 expression. pCR was observed in 57.6% (95% CI: 49.7-65.2) of patients treated with Tecentriq in combination with chemotherapy, an increase of 16.5% from 41.1% (95% CI: 33.6-48.9) in patients treated with placebo plus chemotherapy (one-sided p=0.0044, significance boundary = 0.0184) in the intention-to-treat (ITT) population. The safety profile was consistent with the established profile of the individual medicines and no new safety concerns were identified.

The IMpassion031 study is the second positive Phase III study from Genentech demonstrating the benefit of Tecentriq in TNBC, and the first Tecentriq study to demonstrate benefit in early TNBC. Tecentriq in combination with nab-paclitaxel is currently approved in more than 70 countries worldwide, including the United States and across Europe, for the treatment of adults with unresectable locally advanced or metastatic TNBC in people whose tumors express PD-L1 (IC‰¥1%).

The final overall survival (OS) analysis of the Phase III IMpassion130 study, evaluating Tecentriq in combination with nab-paclitaxel compared with placebo plus nab-paclitaxel as a first-line treatment for patients with metastatic TNBC, was consistent with the first and second interim analyses. There was no significant difference in OS between the treatment groups in the ITT population. Clinically meaningful improvements in OS were seen with Tecentriq plus nab-paclitaxel in PD-L1-positive patients. The magnitude of OS improvements with Tecentriq in PD-L1-positive patients remained clinically meaningful, with an increase of 7.5 months in median OS with Tecentriq plus nab-paclitaxel compared with placebo plus nab-paclitaxel (hazard ratio [HR]=0.67 [95% CI: 0.53“0.86]). However, this result could not be formally tested due to the prespecified statistical testing hierarchy. The cumulative safety of the Tecentriq plus nab-paclitaxel combination remains consistent with the previously reported safety data for this study and the known risks of individual study medicines. No new safety concerns were identified with longer follow-up.

Finally, results from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel compared with placebo plus paclitaxel as a first-line treatment for patients with metastatic TNBC, did not show significant improvement for progression-free survival (PFS) in the PD-L1-positive population (HR=0.82 [95% CI: 0.60-1.12]). The OS data showed a negative trend; however, the study was not powered for the secondary endpoint of OS, and OS data were immature at the time of analysis (initial HR=1.55 [95% CI: 0.86-2.80] in the PD-L1-positive population, based on 21% of patients with an event; updated HR=1.12 [95% CI: 0.76-1.65], updated analysis based on 41% of patients with an event). The safety profile of Tecentriq plus paclitaxel was consistent with the established safety profile of the individual study medicines and no new safety concerns were identified.

Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across several types of lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

About the IMpassion031 study

The IMpassion031 study is a Phase III, multi-center, randomized, double-blind study evaluating the efficacy and safety of Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [albumin-bound paclitaxel; nab-paclitaxel]; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy, in people with previously untreated, early TNBC. The primary endpoint is pCR using the American Joint Committee on Cancer (AJCC) staging system in the intention-to-treat (ITT) population and in the PD-L1-positive population. Secondary endpoints include overall survival (OS), event-free survival, disease-free survival and quality of life measures.

About the IMpassion130 study

The IMpassion130 study is a Phase III, multicenter, randomized, double-blind study evaluating the efficacy, safety and pharmacokinetics of Tecentriq plus nab-paclitaxel compared with placebo plus nab-paclitaxel in people with unresectable locally advanced or metastatic TNBC who have not received prior systemic therapy for metastatic breast cancer. The study enrolled 902 people who were randomized equally (1:1). The co-primary endpoints are PFS per investigator assessment (RECIST 1.1), and OS in the ITT population and PD-L1-positive population. Secondary endpoints include objective response rate and duration of response.

About the IMpassion131 study

The IMpassion131 study is a Phase III, multi-center, randomized, double-blind study evaluating the efficacy and safety of Tecentriq in combination with paclitaxel, in comparison to placebo plus paclitaxel, in people with previously untreated, inoperable, locally advanced or metastatic TNBC. The study enrolled 651 people who were randomized in a 2:1 ratio to receive Tecentriq or placebo plus paclitaxel. The primary endpoint is PFS per investigator assessment (RECIST 1.1) in the PD-L1-positive population, followed by intention-to-treat (ITT) population. Secondary endpoints include OS, objective response rate, and duration of response in the PD-L1-positive and ITT populations.

About triple-negative breast cancer

Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society, close to 280,000 people in the United States will be diagnosed with invasive breast cancer, and more than 42,000 will die from the disease in 2020. Breast cancer is not one, but many diseases based on the biology of each tumor. In triple-negative breast cancer, tumor cells lack hormone receptors and do not have excess HER2 protein. Approximately 15 percent of breast cancers are triple-negative based on the results of diagnostic tests. It is an aggressive form of the disease with few treatment options.

About Tecentriq (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

Tecentriq U.S. Indications (pronounced ˜tÄ“-SEN-trik)

Tecentriq is a prescription medicine used to treat adults with:

A type of bladder and urinary tract cancer called urothelial carcinoma.

Tecentriq may be used in patients with urothelial carcinoma if their bladder cancer has spread or cannot be removed by surgery, and if they have any one of the following conditions:

  • They are not able to take chemotherapy that contains a medicine called cisplatin and their cancer tests positive for PD-L1 or
  • They are not able to take chemotherapy that contains any platinum regardless of the levels of PD-L1 status or
  • They have tried chemotherapy that contains platinum and it did not work or is no longer working.

The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit.

A type of lung cancer called non-small cell lung cancer (NSCLC).

Tecentriq may be used alone as the first treatment in patients with lung cancer if:

  • Their cancer has spread or grown and
  • Their cancer tests positive for high PD-L1, and
  • Their tumor does not have an abnormal EGFR or ALK gene.

Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as the first treatment in patients with lung cancer if:

  • Their cancer has spread or grown, and
  • Is a type called non-squamous NSCLC, and
  • Their tumor does not have an abnormal EGFR or ALK gene.

Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as the first treatment in patients with lung cancer if:

  • Their cancer has spread or grown, and
  • Is a type called non-squamous NSCLC, and
  • Their tumor does not have an abnormal EGFR or ALK gene.

Tecentriq may be used alone in patients with lung cancer if:

  • Their cancer has spread or grown and
  • They have tried chemotherapy that contains platinum, and it did not work or is no longer working.
  • If a patients tumor has an abnormal EGFR or ALK gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

A type of breast cancer called triple-negative breast cancer (TNBC).

Tecentriq may be used with the medicine paclitaxel protein-bound in patients with TNBC when their breast cancer:

  • Has spread or cannot be removed by surgery and
  • Their cancer tests positive for PD-L1.

The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit.

A type of lung cancer called small cell lung cancer (SCLC).

  • Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as the first treatment in patients with SCLC when their lung cancer is a type of lung cancer called extensive-stage small cell lung cancer, which means that it has spread or grown.

A type of liver cancer called hepatocellular carcinoma (HCC).

Tecentriq may be used with the medicine bevacizumab when a patients liver cancer:

  • Has spread or cannot be removed by surgery, and
  • The patient has not received other medicines by mouth or injection through their vein (IV) to treat their cancer.

A type of skin cancer called melanoma.

Tecentriq may be used with the medicines cobimetinib and vemurafenib when a patients melanoma:

  • Has spread or cannot be removed by surgery, and
  • Their cancer has a certain type of abnormal BRAF gene. Their healthcare provider will perform a test to make sure this Tecentriq combination is right for them.

It is not known if Tecentriq is safe and effective in children.

Important Safety Information

The most important information about Tecentriq is:

Tecentriq can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.

Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these symptoms get worse.

Tecentriq can cause serious side effects, including:

  • Lung problems (pneumonitis)“signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath and chest pain
  • Liver problems (hepatitis)“signs and symptoms of hepatitis may include yellowing of the skin or the whites of the eyes, severe nausea or vomiting, pain on the right side of the stomach area (abdomen), drowsiness, dark urine (tea-colored), bleeding or bruising more easily than normal and feeling less hungry than usual
  • Intestinal problems (colitis)“signs and symptoms of colitis may include diarrhea (loose stools) or more bowel movements than usual; blood or mucus in stools or dark, tarry, sticky stools; and severe stomach area (abdomen) pain or tenderness
  • Hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary)“signs and symptoms that the hormone glands are not working properly may include headaches that will not go away or unusual headaches, extreme tiredness, weight gain or weight loss, dizziness or fainting, feeling more hungry or thirsty than usual, hair loss, changes in mood or behavior (such as decreased sex drive, irritability, or forgetfulness), feeling cold, constipation, the voice gets deeper, urinating more often than usual, nausea or vomiting and stomach area (abdomen) pain
  • Problems in other organs“signs and symptoms may include severe muscle weakness, numbness or tingling in hands or feet, confusion, blurry vision, double vision, or other vision problems, changes in mood or behavior, extreme sensitivity to light, neck stiffness, eye pain or redness, skin blisters or peeling, chest pain, irregular heartbeat, shortness of breath or swelling of the ankles
  • Severe infections“signs and symptoms of infection may include fever, cough, flu-like symptoms, pain when urinating and frequent urination or back pain
  • Severe infusion reactions“signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, swelling of the face or lips, dizziness, fever, feeling like passing out and back or neck pain

Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may delay or completely stop treatment with Tecentriq if patients have severe side effects.

Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:

  • Have immune system problems (such as Crohns disease, ulcerative colitis, or lupus); have had an organ transplant; have lung or breathing problems; have liver problems; have a condition that affects the nervous system (such as myasthenia gravis or Guillain-Barre syndrome); or are being treated for an infection.
  • Are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant:
    • Should have a healthcare provider do a pregnancy test before they start treatment with Tecentriq and
    • Should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq.
  • Are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq.

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

  • Feeling tired or weak
  • Nausea
  • Cough
  • Shortness of breath
  • Decreased appetite

The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:

  • Feeling tired or weak
  • Nausea
  • Hair loss
  • Constipation
  • Diarrhea
  • Decreased appetite

The most common side effects of Tecentriq when used in TNBC with paclitaxel protein-bound include:

  • Hair loss
  • Tingling or numbness in hands and feet
  • Feeling tired
  • Nausea
  • Diarrhea
  • Low red blood cells (anemia)
  • Constipation
  • Cough
  • Headache
  • Low white blood cells
  • Vomiting
  • Decreased appetite

The most common side effects of Tecentriq when used in hepatocellular carcinoma with bevacizumab include:

  • High blood pressure
  • Feeling tired or weak
  • Too much protein in the urine

The most common side effects of Tecentriq when used in melanoma with cobimetinib and vemurafenib include:

  • Skin rash
  • Pain in the joint muscle or bone
  • Feeling tired or weak
  • Liver injury
  • Fever
  • Nausea
  • Itching
  • Swelling of legs or arms
  • Swelling of the mouth (sometimes with sores)
  • Underactive thyroid gland
  • Skin sensitivity to sunlight

Tecentriq may cause fertility problems in females, which may affect their ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.

These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information. Patients should call their doctor for medical advice about side effects of Tecentriq.

Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.

Please visit http://www.Tecentriq.com for the full Tecentriq Prescribing Information for additional Important Safety Information.

About Genentech in cancer immunotherapy

Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system.

In addition to Genentechs approved PD-L1 checkpoint inhibitor, the companys broad cancer immunotherapy pipeline includes other checkpoint inhibitors, individualized neoantigen therapies and T cell bispecific antibodies. For more information visit http://www.gene.com/cancer-immunotherapy.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Media Contact: K. Bruneau (650) 467-6800

Advocacy Contact: Lauren Davis (650) 745-5210

Investor Contacts: Lisa Tuomi (650) 467-8737

Karl Mahler 011 41 61 687 8503

News

YOFC Presents at China International Information and Communications Exhibition 2020

gbafNews28

BEIJING, Oct. 20, 2020 /PRNewswire/ — Along with its product lineup and solutions designed to empower the deployment of 5G Internet, leading edge and intelligent applications in the future, Yangtze Optical Fibre and Cable Joint Stock Limited Company ("YOFC" or "the Company") (601869.SH, 06869.HK), a global leading optical fibre and cable provider, attended the China International Information and Communications Exhibition (PT Expo) 2020 organized by the Ministry of Industry and Information Technology of China.

YOFC's Exhibition Booth at China International Information and Communications Exhibition 2020
YOFC’s Exhibition Booth at China International Information and Communications Exhibition 2020

At the YOFC booth, the Company’s Space Division Multiplexing (SDM) solution for next-generation data centres took central stage. The solution was created based on new multi-core fibre technology, suitable for 800Gb and beyond systems, addressing the urgent demands of data centres for bigger capacity, longer transmission distance, high-density connections and low energy consumption. Also sharing the spotlight was the Company’s latest innovations in optical communications and materials.

New Products and Solutions Helping to Develop New Infrastructure Powered by Next-Gen Information Networks and 5G

YOFC’s robust industrial expertise and over 30-year exploration in ICT have enabled the Company to flesh out a product and solution roadmap that empowers the development of a new type of infrastructure enabled by next-gen information networks. With a global rollout of 5G on the horizon, YOFC showcased innovations covering five main categories to meet with pressing new infrastructure needs in the 5G era, which are 5G Series Products and Solutions, Power Grid Communication, Industrial Internet, Big Data Centers and Rail Transportation.

Building a robust 5G ecosystem requires new fibre, cable and optical modules with excellent quality and high efficiency. YOFC has developed solutions for various intelligent applications that will help accelerate a transition to 5G and the Internet of Everything. As part of the product lineup and solutions for 5G facilities, YOFC showcased MWDM Front-haul Solution,Cable Solution for Carrier Network and Optical Transceiver for 5G.

For the sophisticated and complex networks of ultra-high-voltage electricity transmission (UHV), To address these challenges, YOFC presented its latest products designed for a cleaner, safer, and more efficient modern energy system. Amongst these offerings, the G.654.E fibre features ultra-low attenuation with a large effective area, high-fibre-count OPGW cables, and icing monitoring system.

Green, flexible, fast and intelligent, these are some of the key features that define the future of big data centres. YOFC has developed integrated cabling solutions for data centres that feature high density, high performance, reliability and scalability. Products such as optical transceivers and all-in-one cabinets using edge-computing-integrated infrastructure, achieve more effective connectivity and reliable security for network transmission and information processing for data centres.

For rail transportation, YOFC has been leveraging its strength in cable manufacturing to develop numerous technologies for urban rail transit that achieve full bands, wide coverage and low attenuation, including 5G broadband radiation-mode leaky coaxial cable, distributed temperature system and distributed vibration monitoring system. These technologies accommodate the demands of urban rail systems for communication and promote the application of digital technologies in urban rail transportation.

Smart Ocean and Home Solutions

YOFC offers diversified products and solutions for smart tourism, smart communities, and smart education that provide a wide range of smart services, focuses on F5G all-optical network and transforming from "Fibre to the Home (FTTH)" to "Fibre to Everywhere" by expanding the application of the optical technology to all service scenarios. At the exhibition, YOFC presented its key technologies for the ocean and home.

  • Smart Ocean Solutions: YOFC showcased submarine optical cables to be used in various transoceanic communication systems applicable for both deep and shallow sea. The solution also features alternating (direct) current submarine (photoelectric composite) cables for power transmission;
  • Smart Home Solutions: including YOFC’s original BendRobust™ speciality bend-resistant fibre and self-developed high-efficiency photoelectric conversion chip which can maintain high performance and stability across various complex environments.

As information and communication technology (ICT) continues to revolutionize people’s way of life, YOFC continues its commitment to the core mission of establishing a smart link to create a better life, and serving global customers with innovation-led, high-performance and high-quality products; joining efforts with global partners to build a brighter future.

Related Stocks:
HongKong: 06869  
Shanghai: 601869 

Related Links:
https://en.yofc.com/

Related Links :

http://www.yofc.com

Continue Reading

News

IT Tech Packaging, Inc. Participated the ALL IN PRINT CHINA Exhibition

gbafNews28

BAODING, China, Oct. 20, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE MKT: ITP) ("IT Tech Packaging" or "the Company"), a leading manufacturer and distributor of diversified paper products in North China, today announced its CEO Mr. Zhenyong Liu together with its marketing team participated The 8th All In Print China Exhibition held in Shanghai City, the first comprehensive exhibition in printing and packaging business after the COVID-19 epidemic outbreak. The roaring trade released a strong signal of the positive recovery of the printing and packaging industry.

ITP partivipated The All In Print China
ITP partivipated The All In Print China

Mr. Zhenyong Liu, the CEO and Chairman of the Company commented: "the printing and packaging industry is improving as the domestic economy continues recovering, and so is the company. The two-day visit gave us a deep understanding about the latest materials, techniques and products. We will follow the industry trend and strive for a better performance with more advanced producing technology and product quality."

About IT Tech Packaging, Inc.

Founded in 1996, IT Tech Packaging, Inc. is a leading manufacturer and distributor of diversified paper products in North China. Using recycled paper as its primary raw material (with the exception of its tissue paper products), ITP produces and distributes three categories of paper products: corrugating medium paper, offset printing paper and tissue paper products. With production based in Baoding and Xingtai in North China’s Hebei Province, ITP is located strategically close to the Beijing and Tianjin region, home to a growing base of industrial and manufacturing activities and one of the largest markets for paper products consumption in the country. ITP has been listed on the NYSE MKT since December 2009.

Safe Harbor Statements

This press release may contain forward-looking statements. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange Commission, including the Company’s latest annual report on Form 10-K. All information provided in this press release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or revise its forward-looking statements.

For more information, please contact:

At the Company Email:
[email protected]
Tel: +86 0312 8698215

Related Links :

http://www.itpackaging.cn/

Continue Reading

News

Senmiao Technology Announces Signing of Framework Agreement with BYD to Purchase and Jointly Promote Electric Vehicles for Ride-Sharing

gbafNews28

CHENGDU, China, Oct. 20, 2020 /PRNewswire/ — Senmiao Technology Limited ("Senmiao") (NASDAQ: AIHS), a provider of automobile transaction and related services targeting the online ride-hailing industry in China, today announced the signing of a Framework Agreement with BYD Auto Sales Co., Ltd., a wholly owned subsidiary of BYD Company Limited ("BYD",(HK:1211)), for the sale of BYD manufactured electric vehicles ("EVs") to Senmiao and joint promotion of EV vehicles for utilization in China’s ride-sharing or ride-hailing market.

Under the agreement, Senmiao has agreed to promote and give priority to BYD’s EVs for its leasing customers utilizing the vehicles for the purposes of ride-sharing, while BYD will provide favorable pricing, financial support, charging station priority, marketing, and after-sales service. As part of the agreement, Senmiao will provide an initial deposit and expects to purchase at least 5,000 vehicles from 2020 to 2021 to support expected ride-sharing growth.

Senmiao currently ranks first in the ride sharing market in large Chinese cities Chengdu (based in Sichuan Province with a population over 16 million) and Changsha (based in Hunan province with a population over 8 million).  Senmiao has focused on growing its leading position in its core markets, and believes this agreement will help to accelerate its growth given the high demand for EVs and energy efficient automobiles.

In April 2020, China announced a Three-Year-Blue-Sky-Action Plan to accelerate the adoption of EVs. In addition, following the impact of the COVID-19 pandemic, China extended monetary incentives and prolonged purchase-tax exemptions of new EVs through 2022.

BYD is one of the largest manufacturers of automobiles, battery-powered bicycles, buses, trucks, forklifts, solar panels, rechargeable batteries, and most notably mobile-phone batteries.

Xi Wen, Senmiao’s Chairman and Chief Executive Officer stated, "We are delighted to enter into this framework agreement with such a well-regarded company as BYD as we continue to promote the use of EVs in public transportation. We feel that the combination of our position in the ride-sharing markets where we operate along with the demand for EVs in China generally will be an exceptional fit for our customers. Our goal is to provide a wide range of financing and leasing options as we build out Senmiao’s network throughout China, and agreements such as this are instrumental to achieving appropriate scale."

Weiming Zhang, the vice general manager of BYD Auto Sales Co., Ltd. noted, "We are pleased to partner with Senmiao and look forward to supporting the expansion of EV automobiles in the ride-sharing market."

The framework agreement sets out the general terms of the parties intentions for their collaboration, with the goal reaching a more definitive agreement as the collaboration matures.

About Senmiao Technology Limited

Headquartered in Chengdu, Sichuan Province, Senmiao provides automobile transaction and related services including sales of automobiles, facilitation and services for automobile purchase and financing, management, operating lease, guarantee and other automobile transaction services aimed principally at the growing ride-sharing market in Senmiao’s areas of operation in China. For more information about Senmiao, please visit: http://www.senmiaotech.com.

Cautionary Note Regarding Forward-Looking Statements 

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements also are subject to risks, uncertainties and assumptions, including those detailed from time to time in the Senmiao’s filings with the SEC, and represent Senmiao’s views only as of the date they are made and should not be relied upon as representing Senmiao’s views as of any subsequent date. Senmiao undertakes no obligation to publicly revise any forward-looking statements to reflect changes in events or circumstances. 

For more information, please contact:

At the Company:
Yiye Zhou
Email: [email protected]
Phone: +86 28 6155 4399

Investor Relations:

The Equity Group Inc. 
Adam Prior, Senior Vice President 
(212) 836-9606  
[email protected] 

In China
Lucy Ma, Associate
+86 10 5661 7012
[email protected]

© 2020 Senmiao Technology Ltd.  All rights reserved.

 

Related Links :

http://www.senmiaotech.com

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News49 mins ago

Mercury Derivatives Trading Selects Eventus Systems for Trade Surveillance

Global Futures Proprietary Trading Firm Deploys Validus Platform AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ — Eventus Systems, Inc., a multi-award winning...

gbafNews28 gbafNews28
News49 mins ago

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy...

gbafNews28 gbafNews28
News49 mins ago

Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment

INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ — Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona,...

gbafNews28 gbafNews28
News49 mins ago

CoinLock Announces Collaboration with Idoneus, IDON Token Available on Platform Today

– IDON luxury asset token to begin trading on the platform today. – IDON users can now enjoy more utility—like free hedging...

gbafNews28 gbafNews28
News49 mins ago

ATIF Holdings Limited Signs Letter of Intent to Acquire Illuminated Air Purification Solution Provider to Expand into Healthcare Technology Field

SHENZHEN, China, Oct. 20, 2020 /PRNewswire/ — ATIF Holdings Limited (Nasdaq: ATIF, the "Company"), a company providing business consulting and multimedia...

gbafNews28 gbafNews28
News49 mins ago

Over A Million Products On Sale During Banggood’s 11.11 Global Shopping Festival

GUANGZHOU, China, Oct. 20, 2020 /PRNewswire/ — Banggood, a leading cross-border e-commerce retailer, is offering exclusive discounts for its global...

gbafNews28 gbafNews28
News49 mins ago

Senmiao Technology Announces Signing of Framework Agreement with BYD to Purchase and Jointly Promote Electric Vehicles for Ride-Sharing

CHENGDU, China, Oct. 20, 2020 /PRNewswire/ — Senmiao Technology Limited ("Senmiao") (NASDAQ: AIHS), a provider of automobile transaction and related...

gbafNews28 gbafNews28
News49 mins ago

IT Tech Packaging, Inc. Participated the ALL IN PRINT CHINA Exhibition

BAODING, China, Oct. 20, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE MKT: ITP) ("IT Tech Packaging" or "the Company"),...

gbafNews28 gbafNews28
News49 mins ago

YOFC Presents at China International Information and Communications Exhibition 2020

BEIJING, Oct. 20, 2020 /PRNewswire/ — Along with its product lineup and solutions designed to empower the deployment of 5G...

gbafNews28 gbafNews28
News49 mins ago

Aberdeen’s green stone coating expands into USA

TAIPEI, TAIWAN – Media OutReach – 20 October 2020 – The faux stone coating for buildings, a green product developed and...